NUMA1

Summary

NUMA1 (nuclear mitotic apparatus protein 1, HGNC:8059) is a protein-coding gene on chromosome 11q13.4, encoding Nuclear mitotic apparatus protein 1 (Q14980). Microtubule (MT)-binding protein that plays a role in the formation and maintenance of the spindle poles and the alignement and the segregation of chromosomes during mitotic cell division. It is a selective cancer dependency (DepMap: 49.8% of cell lines).

This gene encodes a large protein that forms a structural component of the nuclear matrix. The encoded protein interacts with microtubules and plays a role in the formation and organization of the mitotic spindle during cell division. Chromosomal translocation of this gene with the RARA (retinoic acid receptor, alpha) gene on chromosome 17 have been detected in patients with acute promyelocytic leukemia. Alternative splicing results in multiple transcript variants.

Source: NCBI Gene 4926 — RefSeq curated summary.

At a glance

• GWAS associations: 6
• Clinical variants (ClinVar): 256 total — 1 pathogenic
• Phenotypes (HPO): 36
• Druggable target: yes — 1 molecules with ChEMBL bioactivity
• Cancer driver (intOGen): loss-of-function (tumor-suppressor-like) across 2 cancer types
• Cancer dependency (DepMap): dependent in 49.8% of screened cell lines
• MANE Select transcript: NM_006185

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:8059
Approved symbol	NUMA1
Name	nuclear mitotic apparatus protein 1
Location	11q13.4
Locus type	gene with protein product
Status	Approved
Aliases	NUMA
Ensembl gene	ENSG00000137497
Ensembl biotype	protein_coding
OMIM	164009
Entrez	4926

Gene structure

Transcript identifiers

Ensembl transcripts: 54 — 43 protein_coding, 5 retained_intron, 5 protein_coding_CDS_not_defined, 1 nonsense_mediated_decay

ENST00000351960, ENST00000358965, ENST00000366394, ENST00000368959, ENST00000393695, ENST00000534971, ENST00000534987, ENST00000535087, ENST00000535111, ENST00000535838, ENST00000535947, ENST00000536119, ENST00000537217, ENST00000537905, ENST00000537930, ENST00000540588, ENST00000540626, ENST00000540843, ENST00000541262, ENST00000541584, ENST00000541641, ENST00000541719, ENST00000542977, ENST00000543009, ENST00000543450, ENST00000543937, ENST00000544129, ENST00000544238, ENST00000545721, ENST00000546036, ENST00000546131, ENST00000613205, ENST00000620566, ENST00000863445, ENST00000863446, ENST00000863447, ENST00000863448, ENST00000863449, ENST00000863450, ENST00000863451, ENST00000863452, ENST00000921275, ENST00000921276, ENST00000921277, ENST00000921278, ENST00000967521, ENST00000967522, ENST00000967523, ENST00000967524, ENST00000967525, ENST00000967526, ENST00000967527, ENST00000967528, ENST00000967529

RefSeq mRNA: 2 — MANE Select: NM_006185 NM_001286561, NM_006185

CCDS: CCDS31633, CCDS66156

Canonical transcript exons

ENST00000393695 — 27 exons

Exon	Start	End
ENSE00000927497	72008688	72008845
ENSE00000927498	72008967	72009185
ENSE00000927499	72009268	72009387
ENSE00000927500	72010786	72010854
ENSE00000990252	72012401	72012442
ENSE00001403460	72069842	72069911
ENSE00002439533	72016408	72016530
ENSE00002456033	72017687	72017827
ENSE00002514808	72012895	72016260
ENSE00003486829	72007189	72007435
ENSE00003487481	72018823	72018980
ENSE00003495985	72035902	72035975
ENSE00003522433	72018396	72018513
ENSE00003540906	72022339	72022419
ENSE00003548464	72029205	72029290
ENSE00003619070	72005233	72005369
ENSE00003624289	72004640	72004816
ENSE00003635397	72006035	72006263
ENSE00003637842	72019494	72019617
ENSE00003648558	72004225	72004341
ENSE00003656492	72018183	72018300
ENSE00003683732	72021204	72021291
ENSE00003686017	72024274	72024353
ENSE00003692333	72003887	72004099
ENSE00003693182	72023065	72023147
ENSE00003900323	72002864	72003538
ENSE00003903864	72080458	72080542

Expression profiles

Bgee: expression breadth ubiquitous, 294 present calls, max score 99.27.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 64.5793 / max 355.8293, expressed in 1825 samples.

FANTOM5 promoters (21 alternative TSS)

Promoter ID	TPM avg	Samples expressed
121143	22.0593	1785
121130	20.2812	1729
121141	6.6702	1394
121137	3.4666	939
121135	2.2122	1069
121136	1.8502	788
121142	1.5771	814
121144	1.2795	480
121128	1.2670	703
121140	0.8529	242

Top tissues by expression

294 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
right uterine tube	UBERON:0001302	99.27	gold quality
body of uterus	UBERON:0009853	99.09	gold quality
endocervix	UBERON:0000458	99.01	gold quality
left ovary	UBERON:0002119	98.99	gold quality
right ovary	UBERON:0002118	98.94	gold quality
mucosa of stomach	UBERON:0001199	98.90	gold quality
muscle layer of sigmoid colon	UBERON:0035805	98.90	gold quality
right lobe of thyroid gland	UBERON:0001119	98.84	gold quality
ectocervix	UBERON:0012249	98.84	gold quality
ventricular zone	UBERON:0003053	98.81	gold quality
esophagogastric junction muscularis propria	UBERON:0035841	98.77	gold quality
right hemisphere of cerebellum	UBERON:0014890	98.76	gold quality
skin of abdomen	UBERON:0001416	98.75	gold quality
skin of leg	UBERON:0001511	98.74	gold quality
lower esophagus	UBERON:0013473	98.72	gold quality
lower esophagus muscularis layer	UBERON:0035833	98.72	gold quality
cerebellar hemisphere	UBERON:0002245	98.66	gold quality
left lobe of thyroid gland	UBERON:0001120	98.64	gold quality
cerebellar cortex	UBERON:0002129	98.61	gold quality
tibial nerve	UBERON:0001323	98.58	gold quality
adenohypophysis	UBERON:0002196	98.57	gold quality
ganglionic eminence	UBERON:0004023	98.54	gold quality
left uterine tube	UBERON:0001303	98.53	gold quality
small intestine Peyer’s patch	UBERON:0003454	98.52	gold quality
lower esophagus mucosa	UBERON:0035834	98.50	gold quality
transverse colon	UBERON:0001157	98.47	gold quality
minor salivary gland	UBERON:0001830	98.46	gold quality
right coronary artery	UBERON:0001625	98.45	gold quality
body of stomach	UBERON:0001161	98.40	gold quality
popliteal artery	UBERON:0002250	98.37	gold quality

Single-cell (SCXA)

Detected in 3 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-MTAB-6386	no	868.19
E-MTAB-7303	no	665.33
E-ANND-3	no	0.00

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

46 targeting NUMA1, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4534	99.99	66.58	1907
HSA-MIR-3658	99.96	73.87	4379
HSA-MIR-4725-3P	99.96	69.53	2520
HSA-MIR-6780B-5P	99.96	69.60	2562
HSA-MIR-4487	99.96	64.58	1252
HSA-MIR-8082	99.95	67.27	1170
HSA-MIR-3143	99.93	71.96	3104
HSA-MIR-124-3P	99.89	73.74	3043
HSA-MIR-506-3P	99.89	73.55	3057
HSA-MIR-605-3P	99.88	69.22	1833
HSA-MIR-4271	99.88	68.32	2244
HSA-MIR-548D-3P	99.87	70.67	4362
HSA-MIR-548BB-3P	99.86	70.58	4354
HSA-MIR-548AC	99.84	70.77	4351
HSA-MIR-548H-3P	99.84	70.80	4349
HSA-MIR-548Z	99.84	70.80	4349
HSA-MIR-4699-3P	99.71	70.15	3142
HSA-MIR-1208	99.70	68.28	1533
HSA-MIR-3975	99.62	65.97	697
HSA-MIR-3612	99.45	66.02	1333
HSA-MIR-650	99.45	65.77	1309
HSA-MIR-6882-5P	99.35	71.13	1206
HSA-MIR-4695-5P	99.06	64.87	1151
HSA-MIR-6770-5P	98.97	66.76	1853
HSA-MIR-7155-5P	98.65	66.14	1290
HSA-MIR-4700-5P	98.63	67.43	1915
HSA-MIR-6873-5P	98.45	66.14	1417
HSA-MIR-5088-3P	98.29	66.63	1310
HSA-MIR-8089	97.74	66.21	1698
HSA-MIR-4667-5P	97.61	66.67	1683

Functional genomics

DepMap (CRISPR cell-line fitness): dependent in 49.8% of screened cell lines.

Literature-anchored findings (GeneRIF, showing 40)

• A domain within the C-terminal tail of NuMA interacts with tubulin and induces bundling and stabilisation of microtubules and leads to formation of abnormal mitotic spindles. (PMID:11956313)
• NuMA is cleaved differently in Jurkat T and HeLa cells, suggesting that different sets of caspases are activated in these cell lines. The normal diffuse intranuclear distribution of NuMA changed during apoptosis. (PMID:12508117)
• role in development of myelodi leukemia with promyelocytic features (PMID:14737102)
• Proteins and open reading frames with a NuMA C terminus distal portion like region were found in a diverse set of vertebrate species including mammals, birds, amphibia, and early teleost fish. (PMID:15388855)
• Multiple mechanisms regulate NUMA1 dynamics at spindle poles. (PMID:15561764)
• concluded that variations in the NuMA gene are likely responsible for the observed increased breast cancer risk (PMID:15684076)
• NuMA plays diverse important roles in vertebrate cells [review] (PMID:16146802)
• NuMA has a role in mammary epithelial differentiation by influencing the organization of chromatin. (PMID:17108325)
• point to the Rae1-NuMA interaction as a critical element for normal spindle formation in mitosis (PMID:17172455)
• NuMA is a structural element in maintaining nuclear integrity. (PMID:17401638)
• critical spindle pole-associated mechanism, called the END (Emi1/NuMA/dynein-dynactin) network, that spatially restricts APC/C activity in early mitosis (PMID:17609108)
• The entire coding region and exon-intron boundaries of NuMa were screened in 92 familial breast cancer patients & the results do not support the role of NuMA variants as breast cancer susceptibility alleles. (PMID:18331640)
• Kaposi’s sarcoma-associated herpesvirus-encoded LANA can interact with the nuclear mitotic apparatus protein to regulate genome maintenance and segregation. (PMID:18417561)
• Inhibiting Crm1 in early metaphase causes the formation of excess acentriolar spindle poles containing NuMA and B23, but does not affect centrosome numbers. (PMID:19522705)
• The levels of urinary NMP22 and CK18 in the patients with transitional cell carcinoma of the bladder were significantly higher than those in the non-transitional cell carcinoma of the bladder. (PMID:19615282)
• Data suggest that pADPr provides a dynamic cross-linking function at spindle poles by extending from covalent modification sites on PARP-5a and NuMA and binding noncovalently to NuMA and that this function helps promote assembly of exactly two poles. (PMID:19759176)
• These results suggest that NuMA may provide structural support in the interphase nucleus by contributing to the organization of chromatin. (PMID:20467816)
• Ric-8A and Gi alpha recruit LGN, NuMA, and dynein to the cell cortex to help orient the mitotic spindle. (PMID:20479129)
• Phenotype onset is correlated with NuMA-RARalpha copy number; mice with higher copy number developing disease later than those with lower copy number. (PMID:21255834)
• Accurate distribution of NuMA is important for oocyte maturation, zygote and embryo development in humans. Proper assembly of NuMA is likely necessary for bipolar spindle organization and human oocyte developmental competence. (PMID:21297155)
• NuMA is expressed in interphase nuclei of fibroblasts and oocytes. (PMID:21406448)
• nuclear matrix protein 22 (nuclear mitotic apparatus protein, NuMA) has a role in upper tract urothelial tumors. (PMID:21865670)
• During apoptotic rearrangement of interchromatin granule clusters, the nuclear matrix (NuMa rearrangement) and chromatin are closely associated. This process occurs in defined stages and depends on the activity of protein phosphatases, caspases and CAD. (PMID:22023725)
• Without functional NuMA, microtubules lose connection to meiosis I spindle poles, resulting in highly disorganized early spindle assembly. (PMID:22552228)
• Low NUMA1 is associtated with glioblastoma. (PMID:22619067)
• NuMA expression was upregulated in tumours, with a significant association with disease stage in mucinous EOC subtypes, lymph node involvement and patient age (PMID:22719996)
• Studies indicate that the Inscuteable (Insc)and NuMA are mutually exclusive interactors of LGN. (PMID:22977735)
• Phosphorylation of NuMA by aurora-A is important for cell survival. (PMID:23097092)
• Numa regulates spindle assemby in conjunction with Eg5. (PMID:23368718)
• Data indicate that dynein- and astral microtubule-mediated transport of Galphai/LGN/nuclear mitotic apparatus (NuMA) complex from cell cortex to spindle poles. (PMID:23389635)
• NuMA is required for the recruitment of cyclin-dependent kinase 8, a component of the Mediator complex and a promoter of p53-mediated p21 gene function. (PMID:23589328)
• ectopic expression of BRAP2 inhibits nuclear localization of HMG20A and NuMA1, and prevents nuclear envelope accumulation of SYNE2. (PMID:23707952)
• ectopic expression of NuMA can manipulate endogenous p53 and p21 transcriptional expression during interphase. (PMID:23828576)
• NuMA phosphorylation by CDK1 couples mitotic progression with cortical dynein function. (PMID:23921553)
• Hepatocyte Par1b defines lumen position in concert with the position of the astral microtubule anchoring complex LGN-NuMA to yield the distinct epithelial division phenotypes. (PMID:24165937)
• The mitosis-dependent dynamic SUMO-1 modification of NuMA might contribute to NuMA-mediated formation and maintenance of mitotic spindle poles during mitosis. (PMID:24309115)
• Retinoblastoma protein (pRB) have a novel function in regulating the mitotic function of NuMA and spindle organization, which are required for proper cell cycle progression. (PMID:24350565)
• Study finds that frictional forces increase nonlinearly with microtubule-associated proteins (MAP) velocity across microtubules and depend on filament polarity, with NuMA’s friction being lower when moving toward minus ends, EB1’s lower toward plus ends, and PRC1’s exhibiting no directional preference. (PMID:24725408)
• Letter: risk factors for false positive results when using urinary NMP22 as biomarker for early detection of bladder cancer. (PMID:24976592)
• NuMA interacts with phosphoinositides and links the mitotic spindle with the plasma membrane.During anaphase correct NuMA localization is mediated by direct membrane phospholipid binding. (PMID:24996901)

Cross-species orthologs

4 orthologs

Organism	Symbol	Gene ID
danio_rerio	numa1	ENSDARG00000102483
mus_musculus	Numa1	ENSMUSG00000066306
rattus_norvegicus	Numa1	ENSRNOG00000000417
drosophila_melanogaster	GCC185	FBGN0037979

Paralogs (3): GOLGA3 (ENSG00000090615), CEP164 (ENSG00000110274), GCC2 (ENSG00000135968)

Protein

Protein identifiers

Nuclear mitotic apparatus protein 1 — Q14980 (reviewed: Q14980)

Alternative names: Nuclear matrix protein-22, Nuclear mitotic apparatus protein, SP-H antigen

All UniProt accessions (18): Q14980, F5GWA2, F5GWK2, F5GZW1, F5H068, F5H073, F5H0Z7, F5H1L0, F5H2F3, F5H3L6, F5H4J1, F5H4Y4, F5H6Y5, F5H763, F5H7R5, F8W6T3, H0YFY6, K4DIE0

UniProt curated annotations — full annotation on UniProt →

Function. Microtubule (MT)-binding protein that plays a role in the formation and maintenance of the spindle poles and the alignement and the segregation of chromosomes during mitotic cell division. Functions to tether the minus ends of MTs at the spindle poles, which is critical for the establishment and maintenance of the spindle poles. Plays a role in the establishment of the mitotic spindle orientation during metaphase and elongation during anaphase in a dynein-dynactin-dependent manner. In metaphase, part of a ternary complex composed of GPSM2 and G(i) alpha proteins, that regulates the recruitment and anchorage of the dynein-dynactin complex in the mitotic cell cortex regions situated above the two spindle poles, and hence regulates the correct oritentation of the mitotic spindle. During anaphase, mediates the recruitment and accumulation of the dynein-dynactin complex at the cell membrane of the polar cortical region through direct association with phosphatidylinositol 4,5-bisphosphate (PI(4,5)P2), and hence participates in the regulation of the spindle elongation and chromosome segregation. Also binds to other polyanionic phosphoinositides, such as phosphatidylinositol 3-phosphate (PIP), lysophosphatidic acid (LPA) and phosphatidylinositol triphosphate (PIP3), in vitro. Also required for proper orientation of the mitotic spindle during asymmetric cell divisions. Plays a role in mitotic MT aster assembly. Involved in anastral spindle assembly. Positively regulates TNKS protein localization to spindle poles in mitosis. Highly abundant component of the nuclear matrix where it may serve a non-mitotic structural role, occupies the majority of the nuclear volume. Required for epidermal differentiation and hair follicle morphogenesis.

Subunit / interactions. Homodimer. Also forms multiarm oligomers by association of C-terminal tail domains, oligomers may further assemble to form a hexagonal nuclear lattice-like network. Associates with the dynein-dynactin complex; this association promotes the transport and accumulation of NUMA1 at the mitotic spindle poles that is inhibited by the BRISC complex in a PLK1-dependent manner. Part of a spindle orientation complex at least composed of GNAI1, GPSM2 and NUMA1. Interacts (via C-terminus) with microtubules (MTs); this interaction is direct and promotes both MT bundle formation and stability in a dynein-dynactin complex- and CDK1-independent manner. Interacts with EPB41 and EPB41L2; these interactions are negatively regulated by CDK1 during metaphase and are important for anaphase-specific localization of NUMA1 in symmetrically dividing cells. Interacts (via C-terminus) with GPSM2 (via TPR repeats); this interaction is direct, prevented by competitive binding of INSC, is inhibited in a PLK1-dependent manner, blocks the association of NUMA1 with MTs and inhibits NUMA1-induced MT bundle formation, prevents the association of NUMA1 with SPAG5, induces mitotic spindle pole localization of GPSM2, both metaphase cell cortex localization of NUMA1 and mitotic spindle organization. Does not interact with GPSM2 during anaphase. Interacts (via C-terminus) with the nuclear importin alpha/importin beta receptor; this interaction is inhibited by RanGTP. Interacts (via C-terminus) with KPNB1; this interaction is inhibited by RanGTP and the BRISC complex. Interacts with ABRAXAS2 and the BRISC complex; these interactions regulate mitotic spindle assembly. Interacts (via N-terminal end of the coiled-coil domain) with RAE1; this interaction promotes mitotic spindle formation. Interacts (via C-terminus) with SPAG5 (via C-terminus); this interaction promotes the recruitment of SPAG5 to the MTs at spindle poles in a dynein-dynactin-dependent manner and regulates mitotic spindle organization and proper chromosome alignment during mitosis. Interacts with TNKS; this interaction occurs at the onset of mitosis. Interacts with TNKS2. Interacts with tubulin. Interacts with KHDC3L (via C-terminus).

Subcellular location. Nucleus. Nucleoplasm. Nucleus matrix. Chromosome. Cytoplasm. Cytoskeleton. Microtubule organizing center. Centrosome. Spindle pole. Cell cortex. Cell membrane. Lateral cell membrane Cytoplasm. Cytosol. Spindle pole Cytoplasm.

Post-translational modifications. Phosphorylation and dephosphorylation on Thr-2055 regulates the extent of cortical NUMA1 and the dynein-dynactin complex localization during mitotic metaphase and anaphase. In metaphase, phosphorylation on Thr-2055 occurs in a kinase CDK1-dependent manner; this phosphorylation maintains low levels of cortical dynein-dynactin complex at metaphase, and hence proper spindle positioning. In anaphase, dephosphorylated on Thr-2055 by phosphatase PPP2CA; this dephosphorylation stimulates its membrane association and with the dynein-dynactin complex its enrichment at the cell cortex, and hence robust spindle elongation. Probably also phosphorylated on Thr-2015 and Ser-2087 by CDK1; these phosphorylations may regulate its cell cortex recruitment during metaphase and anaphase. Phosphorylated on Thr-1047, Ser-1769, Ser-1772, Ser-1789 and Ser-1834 by PLK1; these phosphorylations induce cortical dynein-dynactin complex dissociation from the NUMA1-GPSM2 complex and negatively regulates cortical dynein-dynactin complex localization. ADP-ribosylated by TNKS at the onset of mitosis; ADP-ribosylation is not required for its localization to spindle poles. O-glycosylated during cytokinesis at sites identical or close to phosphorylation sites, this interferes with the phosphorylation status. Ubiquitinated with ‘Lys-63’-linked polyubiquitin chains. Deubiquitination by the BRISC complex is important for the incorporation of NUMA1 into mitotic spindle poles and normal spindle pole function, probably by modulating interactions between NUMA1, dynein-dynactin complex and importin-beta.

Domain organisation. The C-terminal tubulin-binding domain mediates direct binding to microtubules, independently of dynein-dynactin complex, and induces their bundling and stabilization. The 4.1-binding domain is necessary for its cortical stability and spindle orientation.

Miscellaneous. Also known as nuclear matrix protein-22/NMP-22/NMP22, an antigen used in diagnostic tests of bladder cancer.

Isoforms (5)

UniProt ID	Names	Canonical?
Q14980-1	1, Numa-1, p230	yes
Q14980-2	2
Q14980-3	3, Numa-m, p195
Q14980-4	4, Numa-s, p194
Q14980-5	5

RefSeq proteins (2): NP_001273490, NP_006176* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR048724	NuMA_N_HOOK	Domain
IPR048726	NuMA_LGNBD	Domain
IPR051841	MT-Golgi_org_protein	Family

Pfam: PF21670

UniProt features (132 total): modified residue 49, region of interest 16, compositionally biased region 16, helix 11, mutagenesis site 9, sequence conflict 7, sequence variant 6, strand 4, cross-link 4, splice variant 4, short sequence motif 2, chain 1, turn 1, coiled-coil region 1, glycosylation site 1

Structure

Experimental structures (PDB)

5 structures.

PDB	Method	Resolution (Å)
6QJA	X-RAY DIFFRACTION	1.54
3RO2	X-RAY DIFFRACTION	2.3
5GXW	X-RAY DIFFRACTION	2.39
6HC2	X-RAY DIFFRACTION	4.31
9HHL	ELECTRON MICROSCOPY	6.53

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q14980-F1	65.19	0.00

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (53): 162, 163, 169, 203, 211, 271, 379, 388, 395, 820, 891, 1047, 1187, 1225, 1511, 1601, 1721, 1724, 1728, 1757 …

Glycosylation sites (1): 1844

Mutagenesis-validated functional residues (9):

Position	Phenotype
1910	abolishes interaction with gpsm2.
1984	no effect on nuclear localization.
1988	abolishes nuclear localization.
2015	abolishes association with the mitotic spindle. increases premature accumulation at the cell cortex during metaphase; wh
2055	increases premature accumulation at the cell membrane of the polar cortical region in prophase and metaphase. reduces as
2055	increases localization at the spindle poles. decreases localization at the cell cortex.
2055	absence of cell membrane association even in anaphase. increased localization at spindle poles and chromosome congressio
2087	abolishes association with the mitotic spindle. increases premature accumulation at the cell cortex during metaphase; wh
2106	abolishes association with the mitotic spindle.

Function

Pathways and Gene Ontology

Reactome pathways

2 pathways

ID	Pathway
R-HSA-380320	Recruitment of NuMA to mitotic centrosomes
R-HSA-68875	Mitotic Prophase

MSigDB gene sets: 479 (showing top): GOBP_POSITIVE_REGULATION_OF_EPITHELIAL_CELL_DIFFERENTIATION, GGGACCA_MIR133A_MIR133B, GOBP_CHROMOSOME_ORGANIZATION, GOBP_ESTABLISHMENT_OF_SPINDLE_ORIENTATION, GOBP_REGULATION_OF_CELLULAR_RESPONSE_TO_GROWTH_FACTOR_STIMULUS, GOBP_EPITHELIUM_DEVELOPMENT, GOBP_PROTEIN_LOCALIZATION_TO_CYTOSKELETON, GOBP_REGULATION_OF_PROTEIN_POLYMERIZATION, GOBP_CYTOPLASMIC_MICROTUBULE_ORGANIZATION, GOBP_ESTABLISHMENT_OR_MAINTENANCE_OF_CELL_POLARITY, GOBP_REGULATION_OF_MICROTUBULE_BASED_PROCESS, GOBP_POSITIVE_REGULATION_OF_KERATINOCYTE_DIFFERENTIATION, GOBP_REGULATION_OF_EPIDERMIS_DEVELOPMENT, GOBP_SPINDLE_LOCALIZATION, GOBP_CHROMOSOME_LOCALIZATION

GO Biological Process (21): establishment of mitotic spindle orientation (GO:0000132), microtubule bundle formation (GO:0001578), nucleus organization (GO:0006997), positive regulation of BMP signaling pathway (GO:0030513), astral microtubule organization (GO:0030953), positive regulation of microtubule polymerization (GO:0031116), positive regulation of intracellular transport (GO:0032388), positive regulation of keratinocyte differentiation (GO:0045618), cell division (GO:0051301), meiotic cell cycle (GO:0051321), positive regulation of hair follicle development (GO:0051798), positive regulation of chromosome segregation (GO:0051984), anastral spindle assembly (GO:0055048), regulation of mitotic spindle organization (GO:0060236), regulation of metaphase plate congression (GO:0090235), positive regulation of protein localization to spindle pole body (GO:1902365), positive regulation of mitotic spindle elongation (GO:1902846), positive regulation of protein localization to cell cortex (GO:1904778), positive regulation of chromosome separation (GO:1905820), positive regulation of spindle assembly (GO:1905832), chromosome segregation (GO:0007059)

GO Molecular Function (12): structural molecule activity (GO:0005198), microtubule binding (GO:0008017), tubulin binding (GO:0015631), protein domain specific binding (GO:0019904), phosphatidylinositol binding (GO:0035091), protein-containing complex binding (GO:0044877), microtubule plus-end binding (GO:0051010), microtubule minus-end binding (GO:0051011), dynein complex binding (GO:0070840), disordered domain specific binding (GO:0097718), protein binding (GO:0005515), lipid binding (GO:0008289)

GO Cellular Component (32): spindle pole (GO:0000922), nucleus (GO:0005634), nucleoplasm (GO:0005654), chromosome (GO:0005694), centrosome (GO:0005813), spindle (GO:0005819), cytosol (GO:0005829), spindle microtubule (GO:0005876), plasma membrane (GO:0005886), cell cortex (GO:0005938), lateral plasma membrane (GO:0016328), nuclear matrix (GO:0016363), dendrite (GO:0030425), spindle pole centrosome (GO:0031616), protein-containing complex (GO:0032991), microtubule plus-end (GO:0035371), microtubule minus-end (GO:0036449), neuronal cell body (GO:0043025), cortical microtubule (GO:0055028), mitotic spindle astral microtubule (GO:0061673), extracellular exosome (GO:0070062), mitotic spindle (GO:0072686), microtubule bundle (GO:0097427), mitotic spindle pole (GO:0097431), lateral cell cortex (GO:0097575), cell cortex region (GO:0099738), cytoplasmic microtubule bundle (GO:1905720), mitotic spindle midzone (GO:1990023), cytoplasm (GO:0005737), cytoskeleton (GO:0005856), microtubule (GO:0005874), membrane (GO:0016020)

Reactome top-level categories

Rollup of top-2 pathways:

Category	Pathways
Mitotic Prometaphase	1
M Phase	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	5
positive regulation of cell cycle process	3
binding	3
positive regulation of multicellular organismal process	2
spindle assembly	2
microtubule binding	2
spindle	2
nuclear lumen	2
intracellular membraneless organelle	2
cytoplasm	2
cell periphery	2
microtubule end	2
mitotic cell cycle	1
establishment of mitotic spindle localization	1
establishment of spindle orientation	1
microtubule cytoskeleton organization	1
organelle organization	1
BMP signaling pathway	1
regulation of BMP signaling pathway	1
positive regulation of transmembrane receptor protein serine/threonine kinase signaling pathway	1
spindle organization	1
cytoplasmic microtubule organization	1
positive regulation of microtubule polymerization or depolymerization	1
regulation of microtubule polymerization	1
positive regulation of protein polymerization	1
microtubule polymerization	1
positive regulation of supramolecular fiber organization	1
regulation of intracellular transport	1
intracellular transport	1
positive regulation of cellular process	1
positive regulation of transport	1
keratinocyte differentiation	1
positive regulation of epidermal cell differentiation	1
regulation of keratinocyte differentiation	1
cellular process	1
cell cycle	1
sexual reproduction	1
reproductive process	1
meiotic nuclear division	1
hair follicle development	1

Protein interactions and networks

STRING

3474 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
NUMA1	GPSM2	P81274	949
NUMA1	HAUS6	Q7Z4H7	919
NUMA1	TNKS	O95271	884
NUMA1	EPB41L2	O43491	834
NUMA1	RARA	P10276	829
NUMA1	NPM1	P06748	817
NUMA1	ZBTB16	Q05516	816
NUMA1	TUBG1	P23258	800
NUMA1	KIF11	P52732	734
NUMA1	KIFC1	Q9BW19	720
NUMA1	HAUS1	Q96CS2	714
NUMA1	HAUS3	Q68CZ6	709
NUMA1	PRKAR1A	P10644	708
NUMA1	HAUS8	Q9BT25	703
NUMA1	DCTN1	Q14203	694

IntAct

189 interactions, top by confidence:

A	B	Type	Score
RAE1	NUP98	psi-mi:“MI:0914”(association)	0.930
HDAC2	KDM1A	psi-mi:“MI:0914”(association)	0.890
MED9	MED19	psi-mi:“MI:0914”(association)	0.790
YEATS4	ZNHIT1	psi-mi:“MI:0914”(association)	0.790
XPC	CETN3	psi-mi:“MI:0914”(association)	0.730
MED19	MED19	psi-mi:“MI:0914”(association)	0.730
RAE1	NUMA1	psi-mi:“MI:0915”(physical association)	0.710
CFTR	ESYT2	psi-mi:“MI:2364”(proximity)	0.710
TNKS2	NUMA1	psi-mi:“MI:0915”(physical association)	0.660
NUMA1	TNKS2	psi-mi:“MI:0407”(direct interaction)	0.660
GPSM2	NUMA1	psi-mi:“MI:0915”(physical association)	0.600
GNAI1	NUMA1	psi-mi:“MI:0915”(physical association)	0.600
NUMA1	GNAI1	psi-mi:“MI:0914”(association)	0.600
NUMA1	GPSM2	psi-mi:“MI:0915”(physical association)	0.600
CCDC57	NUMA1	psi-mi:“MI:0915”(physical association)	0.560
FLJ13057	NUMA1	psi-mi:“MI:0915”(physical association)	0.560
NUMA1	FLJ13057	psi-mi:“MI:0915”(physical association)	0.560
NUMA1	KRT4	psi-mi:“MI:0915”(physical association)	0.560

BioGRID (619): GMCL1 (Two-hybrid), CCDC57 (Two-hybrid), NUMA1 (Affinity Capture-RNA), NUMA1 (Affinity Capture-RNA), NUMA1 (Affinity Capture-RNA), NUMA1 (Two-hybrid), NUMA1 (Affinity Capture-MS), NUMA1 (Affinity Capture-MS), NUMA1 (Affinity Capture-MS), NUMA1 (Affinity Capture-MS), NUMA1 (Affinity Capture-MS), NUMA1 (Affinity Capture-MS), NUMA1 (Affinity Capture-MS), NUMA1 (Affinity Capture-MS), NUMA1 (Affinity Capture-MS)

ESM2 similar proteins: A0JMK8, A0JNT9, A2AUM9, A2BGD5, A6PWD2, A9QT41, B8JK76, E9Q1U1, O75335, O88522, P0CB05, P0CF95, Q08378, Q0KK56, Q14980, Q1LWB0, Q29RS0, Q2KJ21, Q2TAC2, Q3TMW1, Q502I3, Q5RD60, Q5U3A8, Q60952, Q66HR5, Q6DD09, Q6P132, Q6P402, Q6PGZ0, Q6PHN1, Q6TMG5, Q6ZP65, Q804T6, Q8BMK0, Q8CGU1, Q8CHW5, Q8K2I2, Q8K3K8, Q8R5M4, Q8VDC1

Diamond homologs: E9Q7G0, Q14980

SIGNOR signaling

20 interactions.

A	Effect	B	Mechanism
NUMA1	up-regulates	TUBA1B	binding
NUMA1	up-regulates	TUBA1A	binding
NUMA1	up-regulates	TUBA1C	binding
NUMA1	up-regulates	“TUBAC Family”	binding
NUMA1	up-regulates	TUBA3E	binding
NUMA1	up-regulates	TUBA4A	binding
NUMA1	up-regulates	TUBA8	binding
NUMA1	up-regulates	TUBB	binding
NUMA1	up-regulates	TUBB2A	binding
NUMA1	up-regulates	TUBB3	binding
NUMA1	up-regulates	TUBB4A	binding
NUMA1	up-regulates	TUBB4B	binding
NUMA1	up-regulates	TUBB6	binding
NUMA1	up-regulates	TUBD1	binding
NUMA1	up-regulates	TUBG1	binding
CDK1	down-regulates	NUMA1	phosphorylation
NUMA1	up-regulates	Tubulin	binding
EPB41	“up-regulates activity”	NUMA1	relocalization
TBK1	“up-regulates activity”	NUMA1	phosphorylation
PLK1	“down-regulates activity”	NUMA1	phosphorylation

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 210 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
NEP/NS2 Interacts with the Cellular Export Machinery	6	15.1×	9e-04
Nuclear import of Rev protein	6	14.6×	9e-04
Rev-mediated nuclear export of HIV RNA	6	13.8×	9e-04
Transport of Ribonucleoproteins into the Host Nucleus	5	12.9×	3e-03
NS1 Mediated Effects on Host Pathways	6	12.4×	9e-04
Vpr-mediated nuclear import of PICs	5	12.2×	3e-03
Transport of the SLBP independent Mature mRNA	5	11.8×	3e-03
Transport of the SLBP Dependant Mature mRNA	5	11.5×	3e-03

GO biological processes:

GO term	Partners	Fold	FDR
RNA export from nucleus	5	25.2×	3e-04
establishment of mitotic spindle orientation	5	12.9×	6e-03
neuron projection morphogenesis	6	8.9×	8e-03
telomere maintenance	6	8.6×	8e-03
protein import into nucleus	11	8.5×	4e-05
heterochromatin formation	6	8.2×	8e-03
chromatin remodeling	15	5.9×	4e-05
mitotic cell cycle	8	5.8×	8e-03

Disease & clinical

Cancer significance

From intOGen — cancer-driver classification: loss-of-function (tumor-suppressor-like) across 2 cancer types — BRCA, ESCA.

Clinical variants and AI predictions

ClinVar

256 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	1
Likely pathogenic	0
Uncertain significance	189
Likely benign	29
Benign	11

Top pathogenic / likely-pathogenic (1)

Variant ID	HGVS	Classification
1801783	NM_006185.4(NUMA1):c.3716G>C (p.Arg1239Pro)	Pathogenic

SpliceAI

4466 predictions. Top by Δscore:

Variant	Effect	Δscore
11:72003890:G:A	donor_gain	1.0000
11:72004098:GCC:G	acceptor_loss	1.0000
11:72004099:CCT:C	acceptor_loss	1.0000
11:72004100:C:CC	acceptor_gain	1.0000
11:72004219:CCTCA:C	donor_loss	1.0000
11:72004220:CTCAC:C	donor_loss	1.0000
11:72004221:TCAC:T	donor_loss	1.0000
11:72004222:CAC:C	donor_loss	1.0000
11:72004223:A:AC	donor_gain	1.0000
11:72004223:A:AG	donor_loss	1.0000
11:72004224:C:CC	donor_gain	1.0000
11:72004224:C:G	donor_loss	1.0000
11:72004337:TTAGA:T	acceptor_gain	1.0000
11:72004338:TAGA:T	acceptor_gain	1.0000
11:72004339:AGA:A	acceptor_gain	1.0000
11:72004340:GA:G	acceptor_gain	1.0000
11:72004342:C:CC	acceptor_gain	1.0000
11:72004342:C:CG	acceptor_loss	1.0000
11:72004343:T:G	acceptor_loss	1.0000
11:72004344:A:C	acceptor_gain	1.0000
11:72004635:CCTA:C	donor_loss	1.0000
11:72004636:CTA:C	donor_loss	1.0000
11:72004637:TAC:T	donor_loss	1.0000
11:72004638:ACCT:A	donor_loss	1.0000
11:72004639:C:G	donor_loss	1.0000
11:72004812:GAAGG:G	acceptor_gain	1.0000
11:72004813:AAGG:A	acceptor_gain	1.0000
11:72004814:AGG:A	acceptor_gain	1.0000
11:72004814:AGGC:A	acceptor_loss	1.0000
11:72004815:GG:G	acceptor_gain	1.0000

AlphaMissense

13753 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
11:72005285:C:G	R1926P	0.998
11:72005313:A:G	W1917R	0.998
11:72005313:A:T	W1917R	0.998
11:72005261:A:G	L1934P	0.997
11:72005286:G:T	R1926S	0.997
11:72005294:A:G	L1923P	0.997
11:72005311:C:A	W1917C	0.997
11:72005311:C:G	W1917C	0.997
11:72009176:C:G	A1617P	0.997
11:72007224:G:T	R1810S	0.996
11:72005281:A:C	N1927K	0.995
11:72005281:A:T	N1927K	0.995
11:72005257:C:A	K1935N	0.994
11:72005257:C:G	K1935N	0.994
11:72013697:A:G	L1269P	0.994
11:72018214:A:G	L316P	0.994
11:72018256:A:G	L302P	0.994
11:72005306:C:G	R1919P	0.993
11:72007327:G:C	F1775L	0.993
11:72007327:G:T	F1775L	0.993
11:72007329:A:G	F1775L	0.993
11:72018909:A:G	L219P	0.993
11:72005301:C:G	A1921P	0.991
11:72005303:A:C	I1920S	0.991
11:72009153:C:A	K1624N	0.991
11:72009153:C:G	K1624N	0.991
11:72012905:A:G	L1533P	0.991
11:72018286:A:G	L292P	0.991
11:72005303:A:T	I1920N	0.990
11:72008836:C:G	A1690P	0.990

dbSNP variants (sampled 300 via entrez): RS1000061300 (11:72014287 C>T), RS1000067371 (11:72060084 A>G), RS1000076172 (11:72066970 T>C), RS1000094189 (11:72020743 T>C,G), RS1000135636 (11:72061348 G>A), RS1000200302 (11:72027309 C>T), RS1000224007 (11:72050380 A>G), RS1000273913 (11:72027639 T>A,C), RS1000300466 (11:72040764 T>C), RS1000308658 (11:72074341 A>G), RS1000423045 (11:72046974 A>G), RS1000458108 (11:72062016 T>C), RS1000526484 (11:72020922 C>T), RS1000534995 (11:72073020 C>A), RS1000542596 (11:72025693 G>A)

Disease associations

OMIM: gene MIM:164009 | disease phenotypes: MIM:612376, MIM:611451

GenCC curated gene-disease

Mondo (3): myoepithelial tumor (MONDO:0002380), acute promyelocytic leukemia (MONDO:0012883), autosomal recessive nonsyndromic hearing loss 63 (MONDO:0012670)

Orphanet (2): Acute promyelocytic leukemia (Orphanet:520), Rare autosomal recessive non-syndromic sensorineural deafness type DFNB (Orphanet:90636)

HPO phenotypes

36 total (30 of 36 shown, HPO-id order):

HPO	Term
HP:0000212	Gingival overgrowth
HP:0000225	Gingival bleeding
HP:0000421	Epistaxis
HP:0000790	Hematuria
HP:0000967	Petechiae
HP:0000978	Bruising susceptibility
HP:0000979	Purpura
HP:0001324	Muscle weakness
HP:0001824	Weight loss
HP:0001873	Thrombocytopenia
HP:0001875	Decreased total neutrophil count
HP:0001876	Pancytopenia
HP:0001882	Decreased total leukocyte count
HP:0001892	Abnormal bleeding
HP:0001903	Anemia
HP:0001945	Fever
HP:0001974	Increased total leukocyte count
HP:0002027	Abdominal pain
HP:0002039	Anorexia
HP:0002321	Vertigo
HP:0002653	Bone pain
HP:0002716	Lymphadenopathy
HP:0002875	Exertional dyspnea
HP:0005521	Disseminated intravascular coagulation
HP:0010280	Stomatitis
HP:0011900	Hypofibrinogenemia
HP:0012378	Fatigue
HP:0025420	Diffuse alveolar hemorrhage
HP:0030140	Oral cavity bleeding
HP:0030955	Addictive alcohol use

GWAS associations

6 associations (top):

Study	Trait	p-value
GCST002804_1	Antibody level in response to infection	8.000000e-07
GCST003123_25	Severe influenza A (H1N1) infection	8.000000e-17
GCST008790_42	Urinary albumin-to-creatinine ratio	9.000000e-10
GCST008791_13	Microalbuminuria	7.000000e-06
GCST008794_34	Urinary albumin-to-creatinine ratio	2.000000e-09
GCST009640_17	Urinary albumin-to-creatinine ratio	1.000000e-09

EFO canonical traits (4, from GWAS)

EFO ID	Trait name
EFO:0007034	seropositivity measurement
EFO:0007035	Chlamydia pneumoniae seropositivity
EFO:1001488	influenza A (H1N1)
EFO:0007778	urinary albumin to creatinine ratio

MeSH disease descriptors (3)

Descriptor	Name	Tree numbers
D015473	Leukemia, Promyelocytic, Acute	C04.557.337.539.275.700; C15.378.508.539.275.700
D009208	Myoepithelioma	C04.557.435.585
C566951	Deafness, Autosomal Recessive 63 (supp.)

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL5725184 (SINGLE PROTEIN)

Molecules with ChEMBL bioactivity

1 molecules (phase ≥1), by development phase (incl. off-target/promiscuous compounds). Patent mentions across the top 20 by phase: 1,538 (via chembl_molecule»patent_compound — counts attach to the compound, not the gene–compound relationship, so off-target/promiscuous molecules can dominate).

Molecule	Name	Phase	Patents
CHEMBL1232461	MOLIBRESIB	2	1,538

PharmGKB: 1 entry (VIP=true, CPIC=false)

PharmGKB clinical annotations

1 annotations.

Variant	Type	Level	Drugs	Phenotypes
rs10898815	Efficacy	3	Calcium channel blockers	Hypertension

PharmGKB variants

1 variants.

Variant	Genes	Level	Score	#Clin annots	Drugs
rs10898815	NUMA1	3	2.25	1	Calcium channel blockers

ChEMBL bioactivities

6 potent at pChembl≥5 of 6 total, top 6 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
9.51	Kd	0.308	nM	CHEMBL3752910
9.51	ED50	0.308	nM	CHEMBL3752910
7.50	Kd	31.84	nM	CHEMBL5653589
7.50	ED50	31.84	nM	CHEMBL5653589
7.22	Kd	60	nM	MOLIBRESIB
7.05	IC50	90	nM	MOLIBRESIB

PubChem BioAssay actives

4 with measured affinity, of 11 total; 3 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
4-methyl-3-[(1-methyl-6-pyridin-3-ylpyrazolo[3,4-d]pyrimidin-4-yl)amino]-N-[3-(trifluoromethyl)phenyl]benzamide	2148900: Binding affinity to human NUMA1 incubated for 45 mins by Kinobead based pull down assay	kd	0.0003	uM
4-methyl-3-[(2-methyl-6-pyridin-3-ylpyrazolo[3,4-d]pyrimidin-4-yl)amino]-N-[3-(trifluoromethyl)phenyl]benzamide	2148900: Binding affinity to human NUMA1 incubated for 45 mins by Kinobead based pull down assay	kd	0.0318	uM
2-[(4S)-6-(4-chlorophenyl)-8-methoxy-1-methyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepin-4-yl]-N-ethylacetamide	2179160: Binding affinity against NUMA1 (unknown origin) assessed as apparent dissociation constant incubated for 1 hr by colloidal coomassie staining based LC-MS/MS analysis	kd	0.0600	uM

CTD chemical–gene interactions

66 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects expression, increases methylation, affects cotreatment, decreases expression	7
bisphenol A	decreases expression, decreases methylation, increases expression	3
Particulate Matter	increases expression, affects cotreatment, decreases expression, increases abundance	3
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, increases expression, decreases expression	2
Acetaminophen	decreases expression, increases expression	2
Air Pollutants	decreases expression, increases abundance, increases expression	2
Nickel	increases expression	2
N’-(3-bromo-4-hydroxybenzylidene)-2-(9-oxo-10(9H)-acridinyl)acetohydrazide	affects localization	1
FR900359	affects phosphorylation	1
bisphenol F	increases expression	1
TAK-243	increases sumoylation	1
dicrotophos	increases expression	1
bufotalin	decreases expression	1
triphenyl phosphate	affects expression	1
decabromobiphenyl ether	increases expression	1
trichostatin A	decreases expression	1
beta-lapachone	decreases expression	1
sodium arsenite	increases abundance, affects cotreatment, decreases expression	1
butyraldehyde	decreases expression	1
perfluorooctanoic acid	decreases expression	1
manganese chloride	affects cotreatment, decreases expression, increases abundance	1
coumarin	decreases phosphorylation	1
beta-methylcholine	affects expression	1
CGP 52608	affects binding, increases reaction	1
N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride	increases metabolic processing, affects binding, decreases reaction	1
nutlin 3	affects cotreatment, increases secretion	1
ON 01910	affects localization	1
Grape Seed Proanthocyanidins	affects cotreatment, decreases expression	1
dorsomorphin	affects cotreatment, decreases expression	1
2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine	increases expression, increases response to substance	1

ChEMBL screening assays

8 unique, capped per target: 8 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL5651942	Binding	Binding affinity to human NUMA1 incubated for 45 mins by Kinobead based pull down assay	NVP-BHG712: Effects of Regioisomers on the Affinity and Selectivity toward the EPHrin Family. — ChemMedChem

Cellosaurus cell lines

3 cell lines: 2 cancer cell line, 1 transformed cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_A7NI	2XSB	Cancer cell line	Female
CVCL_D7W7	Ubigene A-549 NUMA1 KO	Cancer cell line	Male
CVCL_D9LR	Ubigene HEK293 NUMA1 KO	Transformed cell line	Female

Clinical trials (associated diseases)

56 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00196768	PHASE4	UNKNOWN	Treatment Protocol for Relapsed Acute Promyelocytic Leukemia (APL) With Arsenic
NCT00408278	PHASE4	COMPLETED	Treatment of Newly Diagnosed Patients With Acute Promyelocytic Leukemia (PETHEMA LPA 2005)
NCT00465933	PHASE4	COMPLETED	Treatment of Acute Promyelocytic Leukemia With All-Trans Retinoic Acid (ATRA) and Idarubicin (AIDA)
NCT00504764	PHASE4	COMPLETED	Treatment of Relapsed Promyelocytic Leukemia With Arsenic Trioxide (ATO)
NCT01987297	PHASE4	UNKNOWN	Combined Retinoic Acid,Arsenic Trioxide and Chemo for Newly-diagnosed APL
NCT02020161	PHASE4	UNKNOWN	Clinical Guidelines for APL Treatment
NCT01226303	PHASE3	UNKNOWN	Treatment Study for Children and Adolescents With Acute Promyelocitic Leukemia
NCT02688140	PHASE3	COMPLETED	Study for Patients With Newly Diagnosed, High-risk Acute Promyelocytic Leukemia
NCT02899169	PHASE3	UNKNOWN	Treatment of Non-high-risk Acute Promyelocytic Leukemia (APL) With Realgar-Indigo Naturalis Formula (RIF)
NCT04175587	PHASE3	UNKNOWN	Randomized,International Multi-center Clinical Trial of RIF Plus RA for Non-high-risk APL
NCT07296445	PHASE3	NOT_YET_RECRUITING	A Trial to Investigate Whether Oral Arsenic Trioxide Is Similar to Intravenous Arsenic Trioxide in Pharmacokinetics, Safety, and Efficacy (LATITUDE/SDKARS-301)
NCT07503730	PHASE3	RECRUITING	Early Use of Realgar-Indigo Naturalis Formula (RIF) Combined With All-trans Retinoic Acid (ATRA) for Treating Acute Promyelocytic Leukemia (APL).
NCT07504458	PHASE3	RECRUITING	Pivotal Open-label Phase 3 Clinical Study of QTX-2101 in Adult Patients With Acute Promyelocytic Leukemia
NCT00413166	PHASE2	COMPLETED	All-trans Retinoic Acid, and Arsenic +/- Idarubicin
NCT00520208	PHASE2	COMPLETED	Safety, Efficacy, & Pharmacokinetic Study of Tamibarotene to Treat Patients With Relapsed or Refractory APL
NCT00670150	PHASE2	WITHDRAWN	New Retinoid Agent Combined With Arsenic Trioxide for Untreated Acute Promyelocytic Leukemia
NCT00675870	PHASE2	UNKNOWN	Study of NRX 195183 Therapy for Patients With Relapsed or Refractory Acute Promyelocytic Leukemia
NCT00907582	PHASE2	TERMINATED	ASCT for Relapsed APL After Molecular Remission
NCT01064570	PHASE2	UNKNOWN	AIDA 2000 Guidelines
NCT01253070	PHASE2	COMPLETED	Sorafenib Tosylate and Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia
NCT01404949	PHASE2	COMPLETED	Combined Tretinoin and Arsenic Trioxide for Patients With Newly Diagnosed Acute Promyelocytic Leukemia Followed by Risk-Adapted Postremission Therapy
NCT01409161	PHASE2	RECRUITING	Tretinoin and Arsenic Trioxide With or Without Gemtuzumab Ozogamicin in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia
NCT03624270	PHASE2	UNKNOWN	Oral Arsenic Trioxide for Newly Diagnosed Acute Promyelocytic Leukaemia
NCT04687176	PHASE2	RECRUITING	Frontline Oral Arsenic Trioxide for APL
NCT04793919	PHASE2	RECRUITING	Treatment Study for Children and Adolescents With Acute Promyelocytic Leukemia
NCT05881265	PHASE2	RECRUITING	Treatment of Chidamide and Venetoclax for Retinoic Acid and Arsenic Resistant Acute Promyelocytic Leukemia
NCT06982274	PHASE2	RECRUITING	Oral Arsenic With ATRA for Newly Diagnosed Patients With Acute Promyelocytic Leukemia
NCT03600649	PHASE1	UNKNOWN	Clinical Trial of SP-2577 (Seclidemstat) in Patients With Relapsed or Refractory Ewing or Ewing-related Sarcomas
NCT00852709	PHASE1	TERMINATED	Phase I Dose-Escalation Trial of Clofarabine Followed by Escalating Doses of Fractionated Cyclophosphamide in Children With Relapsed or Refractory Acute Leukemias
NCT00985530	PHASE1	TERMINATED	Tamibarotene and Arsenic Trioxide for Relapsed Acute Promyelocytic Leukemia
NCT01902329	PHASE1	COMPLETED	A Safety Study of SGN-CD33A in AML Patients
NCT02086773	PHASE1	COMPLETED	Red Cell Transfusion Goals in Patients With Acute Leukemias
NCT02390635	PHASE1	RECRUITING	PET/MRI, 18F-FDG PET/CT and Whole Body MRI in Finding Extramedullary Myeloid Leukemia in Patients With Newly Diagnosed Acute Myeloid Leukemia
NCT04996030	PHASE1	SUSPENDED	A Study for Oral SY-2101 for Participants With Acute Promyelocytic Leukemia
NCT06882031	PHASE1	COMPLETED	Evaluate the Pharmacokinetics of Oral Arsenic Trioxide Solution Under Fasting and Fed Conditions, to Compare Intravenous Arsenic Trioxide, in Acute Promyelocytic Leukemia
NCT05266196	PHASE1/PHASE2	UNKNOWN	A Rollover Protocol to Allow for Continued Access to the LSD1 Inhibitor Seclidemstat (SP-2577)
NCT06239272	PHASE1/PHASE2	RECRUITING	NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)
NCT06625190	PHASE1/PHASE2	RECRUITING	Alpha/Beta T and B Cell Depletion With Zoledronic Acid for Solid Tumors
NCT06244420	Not specified	COMPLETED	Malignant Myoepithelioma of Bone and Soft Tissues: Diagnostic Imaging and Histology in Relation to Prognosis
NCT00517712	PHASE2/PHASE3	UNKNOWN	Single Agent Arsenic Trioxide in the Treatment of Newly Diagnosed Acute Promyelocytic Leukemia